Redeye provides a research update following the Q4 report published by Lipum earlier today. While the company reported OPEX above our expectation following preparations ahead of the upcoming phase II trials, the focus is undoubtedly on the recent positive phase I topline results. We are encouraged to learn that the candidate demonstrated a robust safety and tolerability profile, predictable pharmacokinetics and successful suppression of the target protein (BSSL).
LÄS MER
